Results 11 to 20 of about 957,553 (357)

Molecular Targeted Therapy

Siriraj Medical Journal, 2006
-
Nopadol Soparattanapaisarn
doaj   +1 more source

Molecular Pathways: HER3 Targeted Therapy [PDF]

Clinical Cancer Research, 2014
Abstract The HER family of receptor tyrosine kinases, including EGF receptor (EGFR), HER2, HER3, and HER4, transduce growth-promoting signals in response to ligand binding to their extracellular domains (ECD). This family is deregulated in numerous cancers, with mutations in EGFR and HER2 often serving as “driver” events to activate key ...
Kinisha, Gala, Sarat, Chandarlapaty
openaire   +2 more sources

Targeting the key cholesterol biosynthesis enzyme squalene monooxygenasefor cancer therapy

Frontiers in Oncology, 2022
Cholesterol metabolism is often dysregulated in cancer. Squalene monooxygenase (SQLE) is the second rate-limiting enzyme involved in cholesterol synthesis.
Yuheng Zou, Hongying Zhang, Feng Bi, Qiulin Tang, Huanji Xu   +4 more
doaj   +1 more source

Role of oncogenic KRAS in the prognosis, diagnosis and treatment of colorectal cancer

Molecular Cancer, 2021
Colorectal cancer (CRC) is a heterogeneous disease at the cellular and molecular levels. Kirsten rat sarcoma (KRAS) is a commonly mutated oncogene in CRC, with mutations in approximately 40% of all CRC cases; its mutations result in constitutive ...
Gongmin Zhu, Lijiao Pei, Hongwei Xia, Qiulin Tang, Feng Bi   +4 more
doaj   +1 more source

Characteristics and survival of patients with advanced cancer and p53 mutations. [PDF]

, 2014
P53 mutations are associated with invasive tumors in mouse models. We assessed the p53mutations and survival in patients with advanced cancer treated in the Phase I Program. Of 691 tested patients, 273 (39.5%) had p53 mutations.
Aldape, Kenneth, Fu, Siqing, Hess, Kenneth R, Hong, David S, Janku, Filip, Kurzrock, Razelle, Naing, Aung, Palmer, Gary A, Said, Rabih, Thomas, Christoforos, Tsimberidou, Apostolia M, Wheler, Jennifer J, Ye, Yang   +12 more
core   +8 more sources

Molecular pathogenesis and targeted therapy of sporadic pancreatic neuroendocrine tumors [PDF]

, 2015
Over the past few years, knowledge regarding the molecular pathology of sporadic pancreatic neuroendocrine tumors (PNETs) has increased substantially, and a number of targeted agents have been tested in clinical trials in this tumor type.
Ahn, Balogh, Bergers, Berruti, Capurso, Capurso, Carew, Castellano, Chamberlain, Chan, Chan, Chen, Clynes, Corbo, Corbo, Couvelard, De Wilde, Di Florio, Di Florio, Di Florio, Fazio, Fendrich, Gaur, Gurung, Han, Heaphy, Heaphy, Hobday, Hopfner, House, Jacinto, Jensen, Jiao, Karnik, Karnik, Komori, Kulke, Laplante, Loewith, Lovejoy, Luzi, Marinoni, Marion-Audibert, Mendel, Meric-Bernstam, Missiaglia, Mocellin, Panzuto, Papouchado, Passacantilli, Perren, Pàez-Ribes, Raymond, Sarbassov, Scoazec, Shah, Shi, Tang, Vinagre, Wang, Yang, Yao, Yuan, Zhang, Zhang   +64 more
core   +1 more source

Targeted Molecular Therapies for SBMA [PDF]

Journal of Molecular Neuroscience, 2015
Spinal and bulbar muscular atrophy (SBMA) is a late-onset neuromuscular disease caused by a polyglutamine expansion in the androgen receptor gene which results in progressive spinal and bulbar motor neuron degeneration, and muscle atrophy. Although the causative genetic defect is known, until recently, the molecular pathogenesis of the disease was ...
Rinaldi, C, Malik, B, Greensmith, L
openaire   +3 more sources

Patient-centric trials for therapeutic development in precision oncology [PDF]

, 2015
An enhanced understanding of the molecular pathology of disease gained from genomic studies is facilitating the development of treatments that target discrete molecular subclasses of tumours.
A Hollebecque, A-M Tsimberidou, AD Barker, AL Tam, Andrew V. Biankin, AT Shaw, AV Biankin, B Zhang, C Le Tourneau, C Le Tourneau, C Lin, C Printz, CK Lee, CR Lindsay, D Cook, D Slamon, D Zardavas, DD Von Hoff, DE Gerber, DJ Sargent, DT Le, EA Eisenhauer, ED Green, ES Kim, F André, GD Demetri, GM Frampton, IR Watson, J Ledermann, J Lewin, J Verweij, JA Sosman, JY Douillard, L Chin, L Chin, L Seguin, LA Chantrill, LB Alexandrov, LJ Esserman, LJ Esserman, M Hay, M Maemondo, MG Kris, MR Stratton, MR Stratton, N Roper, N Waddell, NM Hylton, PA Jänne, PN Lara Jr, R Dienstmann, R Simon, RR Kalf, S Matsumoto, S Sleijfer, Simon J. Hollingsworth, SJ Dawson, SJ Mandrekar, Steven Piantadosi, TA Yap, TJ Hudson   +60 more
core   +1 more source

Targeting Oncogenic BRAF: Past, Present, and Future. [PDF]

, 2019
Identifying recurrent somatic genetic alterations of, and dependency on, the kinase BRAF has enabled a "precision medicine" paradigm to diagnose and treat BRAF-driven tumors.
Bivona, Trever G, Wu, Wei, Zaman, Aubhishek   +2 more
core   +1 more source

Phenethyl Isothiocyanate Enhances the Cytotoxic Effects of PARP Inhibitors in High-Grade Serous Ovarian Cancer Cells

Frontiers in Oncology, 2022
While PARP inhibitor (PARPi) therapies have shown promising results in the treatment of high-grade serous ovarian cancer (HGSOC) harboring homologous recombination deficiencies, primary resistance to PARPi frequently occurs and even initial responders ...
Yaxun Jia, Min Wang, Xiaolin Sang, Pixu Liu, Jingchun Gao, Kui Jiang, Hailing Cheng   +6 more
doaj   +1 more source